Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Bomedemstat with Carbamazepine in Healthy Adults
NCT06596668Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bomedemstat in myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), myelofibrosis (MF) and 1 more, sponsored by Merck & Co. Primary endpoint: Area under the concentration versus time curve from 0 to infinity. Started Oct 2024; status: completed.
02
Drugs
bomedemstat
03
Conditions
myeloproliferative neoplasms (MPN)essential thrombocythemia (ET)myelofibrosis (MF)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06596668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596668.